This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Parkinson's Disease

In this condition, degenerative changes are found in an area of the brain known as the substantia nigra, which produces dopamine, a chemical substance that enables people to move normally and smoothly. In Parkinson's there's a severe lack of dopamine, which causes the main symptoms - tremor, rigidity, and slowness of movement (bradykinesia).

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Parkinson’s Disease Dementia Study CENA713B2315

The purpose of this clinical trial is to determine the long-term safety of Exelon® capsule and transdermal (through the skin) patch treatments in participants with Parkinson’s disease dementia (PDD) over a period of 18 months (76 weeks). Study participants must have a reliable caregiver who will assist with keeping scheduled appointments, providing and/or applying medication, reporting any problems to the study center staff, and assessing the condition of the participant throughout the study.
Trial phase: Phase 3b
Participation Duration: Participants will be required to visit the study center approximately 10 times over 18 months (76 weeks). Participants assigned to the capsule will take the study medication Exelon® capsule twice a day. Participants assigned to transdermal patch will apply the Exelon® patch once per day which will be worn for 24 hours.
Protocol Number: CENA713B2315

Parkinson’s Disease Study CELC200AUS14

The purpose of this clinical trial is to test the effects and safety of the study drug Stalevo® compared to the effects of immediate-release carbidopa/levodopa on end-of-dose wearing off in participants who are between 30 and 75 years old and have Parkinson’s Disease (PD). End-of-dose wearing off is when symptoms begin to come back before it is time to take the next dose of medicine. The study drug Stalevo® was approved by the United States Food & Drug Administration in June 2003 for the treatment of patients with idiopathic Parkinson’s disease.
Trial phase: Phase 4
Participation Duration: Participants will be required to visit the study center 3 times over an 8 week period.
Protocol Number: CELC200AUS14

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Parkinson's Disease